Cci-779 formulations for parenteral administration
AssigneeWyeth
InventorsJoseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
Life of this patent
Estimating the term…
Abstract
This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
Claims24
A method for administering a parenteral CCI-779 formulation to a subject in need thereof, said method comprising:
- (i) mixing about 1 to about 25 mg/mL of CCI-779, about 15 to about 60% w/v of dehydrated ethanol, about 0.01 to about 0.1% of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, and about 15 to about 60% w/v of propylene glycol to provide a cosolvent concentrate;
- (ii) mixing about 15 to about 60% w/v of polysorbate 80, about 15 to 60% w/v of polyethylene glycol 400, and about 15 to about 60% w/v of dehydrated ethanol to provide a diluent;
- (iii) mixing said cosolvent concentrate and said diluent;
- and
- (iv) administering the product of step (iii) to said subject.
A CCI-779 direct injection fluid, said fluid comprising:
- (i) about 1 to about 25 mg/mL of CCI-779;
- (ii) about 0.01 to about 0.1% w/v of d,1-α-tocopherol;
- (iii) about 0.001 to about 0.005% w/v of citric acid;
- (iv) about 15 to about 60% w/v of a combination of dehydrated ethanol and propylene glycol;
- and
- (v) about 15 to about 60% w/v of a combination of polysorbate 80 and polyethylene glycol 400.
A CCI-779 intravenous infusion solution comprising:
- (i) about 1 to about 25 mg/mL of CCI-779, about 0.01 to about 0.1% w/v of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, about 15 to about 60% w/v of a combination of dehydrated ethanol and propylene glycol, and about 15 to about 60% w/v of a combination of polysorbate 80 and polyethylene glycol 400;
- and
- (ii) a sterile infusion fluid.
A method of solubilizing CCI-779 in a solution, said method comprising mixing about 1 to about 25 mg/mL of CCI-779, about 0.01 to about 0.1% w/v of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, about 15 to about 60% w/v of a combination of dehydrated ethanol and propylene glycol, and about 15 to about 60% w/v of a combination of polysorbate 80 and polyethylene glycol 400.
A method of stabilizing a solution comprising CCI-779, said method comprising mixing about 1 to about 25 mg/mL of said CCI-779 with about 15 to about 60% w/v of dehydrated ethanol, about 0.01 to about 0.1% of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, and about 15 to about 60% w/v of propylene glycol.
A method of stabilizing a solution comprising CCI-779, said method comprising mixing about 1 to about 25 mg/mL of said CCI-779 with about 0.01 to about 0.1% w/v of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, about 15 to about 60% w/v of a combination of dehydrated ethanol and propylene glycol, and about 15 to about 60% w/v of a combination of polysorbate 80 and polyethylene glycol 400.
A method of preventing precipitation of CCI-779 in an aqueous infusion solution or blood, said method comprising:
- (i) mixing about 1 to about 25 mg/mL of CCI-779, about 15 to about 60% w/v of dehydrated ethanol, about 0.01 to about 0.1% of d,1-α-tocopherol, about 0.001 to about 0.005% w/v of citric acid, and about 15 to about 60% w/v of propylene glycol to provide a cosolvent concentrate;
- (ii) mixing about 15 to about 60% w/v of polysorbate 80, about 15 to 60% w/v of polyethylene glycol 400, and about 15 to about 60% w/v of dehydrated ethanol to provide a diluent;
- (iii) mixing said cosolvent concentrate and said diluent;
- and
- (iv) adding the product of step (iii) to said aqueous infusion solution or blood.
Dependencies are inferred from the claim text.